Free Trial

Innate Pharma (IPHA) Short Interest Ratio & Short Volume

Innate Pharma logo
$1.92 +0.13 (+7.26%)
Closing price 04/3/2025 03:51 PM Eastern
Extended Trading
$1.92 +0.00 (+0.05%)
As of 04:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Innate Pharma Short Interest Data

Innate Pharma (IPHA) has a short interest of 417,100 shares, representing 0.73% of the float (the number of shares available for trading by the public). This marks a -9.60% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.8, indicating that it would take 1.8 days of the average trading volume of 182,266 shares to cover all short positions.

Current Short Interest
417,100 shares
Previous Short Interest
461,400 shares
Change Vs. Previous Month
-9.60%
Dollar Volume Sold Short
$812,927.90
Short Interest Ratio
1.8 Days to Cover
Last Record Date
March 15, 2025
Outstanding Shares
83,830,000 shares
Short Percent of Float
0.73%
Today's Trading Volume
70,388 shares
Average Trading Volume
182,266 shares
Today's Volume Vs. Average
39%
Short Selling Innate Pharma?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Innate Pharma and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

IPHA Short Interest Over Time

IPHA Days to Cover Over Time

IPHA Percentage of Float Shorted Over Time

Remove Ads

Innate Pharma Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
3/15/2025417,100 shares $812,927.90 -9.6%0.7%1.8 $1.95
2/28/2025461,400 shares $978,168.00 +199.2%0.8%0.7 $2.12
2/15/2025154,200 shares $299,148.00 +1.1%0.3%0.2 $1.94
1/31/2025152,500 shares $279,075.00 +44.7%N/A0.3 $1.83
1/15/2025105,400 shares $179,180.00 +4.4%N/A0.2 $1.70
12/31/2024101,000 shares $185,840.00 -88.9%N/A0.2 $1.84
12/15/2024909,800 shares $2.75 million +1,344.1%N/A2 $3.02
11/30/202463,000 shares $97,020.00 -1.1%N/A0.3 $1.54
11/15/202463,700 shares $91,728.00 -2.3%N/A6.2 $1.44
10/31/202465,200 shares $123,293.20 +10.9%N/A7.8 $1.89
10/15/202458,800 shares $119,364.00 -18.1%N/A7.4 $2.03
9/30/202471,800 shares $164,422.00 +20.3%N/A10 $2.29
9/15/202459,700 shares $134,922.00 -8.3%N/A9 $2.26
8/31/202465,100 shares $149,404.50 -2.5%N/A9.3 $2.30
8/15/202466,800 shares $150,300.00 +3.6%N/A8.1 $2.25
7/31/202464,500 shares $138,352.50 -11.5%N/A7.8 $2.15
7/15/202472,900 shares $154,548.00 +5.2%N/A9.1 $2.12
6/30/202469,300 shares $134,442.00 -4.9%N/A7.7 $1.94
6/15/202472,900 shares $171,315.00 +4.1%N/A7 $2.35
5/31/202470,000 shares $191,800.00 -0.3%N/A6.7 $2.74
5/15/202470,200 shares $175,942.26 -11.3%N/A7.2 $2.51
4/30/202479,100 shares $182,721.00 -2.7%N/A8.8 $2.31
4/15/202481,300 shares $196,746.00 +5.7%N/A7.8 $2.42
3/31/202476,900 shares $221,472.00 -13.7%N/A7.7 $2.88
3/15/202489,100 shares $217,404.00 +13.7%N/A7.6 $2.44
2/29/202478,400 shares $205,408.00 -4.9%N/A4.1 $2.62
2/15/202482,400 shares $212,592.00 +8.4%N/A4.7 $2.58
1/31/202476,000 shares $203,680.00 -0.9%N/A4 $2.68
1/15/202476,700 shares $214,760.00 -8.9%N/A3.7 $2.80
12/31/202384,200 shares $235,760.00 +55.9%N/A3.9 $2.80
12/15/202354,000 shares $130,140.00 -5.9%N/A2.6 $2.41
11/30/202357,400 shares $137,760.00 -4.3%N/A4.3 $2.40
11/15/202360,000 shares $147,600.00 -6.0%N/A4.2 $2.46
10/31/202363,800 shares $151,844.00 +11.5%N/A4.4 $2.38
10/15/202357,200 shares $132,418.00 -8.5%N/A5 $2.32
9/30/202362,500 shares $158,125.00 -3.4%N/A6 $2.53
9/15/202364,700 shares $192,159.00 -1.5%N/A6.7 $2.97
8/31/202365,700 shares $191,324.97 -8.1%N/A5.2 $2.91
8/15/202371,500 shares $206,635.00 -3.8%N/A6.1 $2.89
7/31/202374,300 shares $218,442.00 -1.9%N/A6.8 $2.94
Trump’s betrayal exposed (Ad)

Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.

Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma
7/15/202375,700 shares $244,511.00 -3.8%N/A6.4 $3.23
6/30/202378,700 shares $242,002.50 +20.0%N/A6.1 $3.08
6/15/202365,600 shares $213,856.00 +9.7%N/A4 $3.26
5/31/202359,800 shares $175,812.00 -4.3%N/A3.8 $2.94
5/15/202362,500 shares $186,875.00 No ChangeN/A3.6 $2.99
10/31/2022147,600 shares $317,340.00 +12.8%N/A12.9 $2.15
10/15/2022130,900 shares $261,800.00 +15.5%N/A12.5 $2.00
9/30/2022113,300 shares $226,600.00 +1.3%N/A12.7 $2.00
9/15/2022111,900 shares $284,226.00 +2.3%N/A13.3 $2.54
8/31/2022109,400 shares $293,192.00 +0.2%N/A6.4 $2.68
8/15/2022109,200 shares $321,048.00 -10.1%N/A5.9 $2.94
7/31/2022121,500 shares $388,787.85 -3.6%N/A6.1 $3.20
7/15/2022126,000 shares $347,760.00 +0.3%N/A4.9 $2.76
6/30/2022125,600 shares $339,120.00 +3.9%N/A4.8 $2.70
6/15/2022120,900 shares $305,877.00 +1.9%N/A4.6 $2.53
5/31/2022118,700 shares $315,742.00 -13.6%N/A6.2 $2.66
5/15/2022137,300 shares $394,051.00 +8.0%N/A6.7 $2.87
4/30/2022127,100 shares $364,777.00 -9.3%N/A5.7 $2.87
4/15/2022140,100 shares $438,513.00 +4.0%N/A6 $3.13
3/31/2022134,700 shares $452,592.00 +105.0%N/A5.3 $3.36
3/15/202265,700 shares $207,612.00 +13.9%N/A1.6 $3.16
2/28/202257,700 shares $196,757.00 -2.5%N/A1 $3.41
2/15/202259,200 shares $219,632.00 -15.6%N/A0.9 $3.71
1/31/202270,100 shares $265,679.00 -15.3%N/A1 $3.79
1/15/202282,800 shares $375,084.00 -22.3%N/A1.1 $4.53
12/31/2021106,600 shares $486,096.00 +247.2%N/A1.3 $4.56
12/15/202130,700 shares $158,105.00 +0.3%N/A0.3 $5.15
11/30/202130,600 shares $151,776.00 -39.8%N/A0 $4.96
11/15/202150,800 shares $263,652.00 +195.4%N/A0 $5.19
10/29/202117,200 shares $99,760.00 +18.6%N/A0 $5.80
10/15/202114,500 shares $85,115.00 -89.5%N/A0 $5.87
9/30/2021137,800 shares $850,226.00 +79.7%N/A0.1 $6.17
9/15/202176,700 shares $427,986.00 +2,456.7%N/A0 $5.58
8/31/20213,000 shares $10,920.00 -45.5%N/A0 $3.64
8/13/20215,500 shares $18,700.00 -35.3%N/A0.3 $3.40
7/30/20218,500 shares $28,220.00 -33.6%N/A0.5 $3.32
7/15/202112,800 shares $41,472.00 +100.0%N/A0.7 $3.24
6/30/20216,400 shares $21,056.00 -61.0%N/A0.4 $3.29
6/15/202116,400 shares $65,764.00 +1,161.5%N/A1.1 $4.01
5/28/20211,300 shares $5,083.00 +225.0%N/A0.1 $3.91
5/14/2021400 shares $1,580.00 -81.8%N/A0 $3.95
4/30/20212,200 shares $9,416.00 -29.0%N/A0.1 $4.28
4/15/20213,100 shares $13,578.00 -55.7%N/A0 $4.38
3/31/20217,000 shares $30,030.00 -6.7%N/A0.2 $4.29
3/15/20217,500 shares $34,275.00 +53.1%N/A0.2 $4.57
2/26/20214,900 shares $21,658.00 -27.9%N/A0.1 $4.42
2/12/20216,800 shares $30,804.00 +385.7%N/A0.2 $4.53
1/29/20211,400 shares $5,740.00 -74.1%N/A0 $4.10
1/15/20215,400 shares $24,516.00 -77.2%N/A0.2 $4.54
12/31/202023,700 shares $102,147.00 -52.5%N/A0.9 $4.31
Trump’s betrayal exposed (Ad)

Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.

Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma
12/15/202049,900 shares $219,061.00 +91.2%N/A2.5 $4.39
11/30/202026,100 shares $145,116.00 -7.1%N/A1.5 $5.56
11/15/202028,100 shares $133,475.00 -23.2%N/A1.6 $4.75
10/30/202036,600 shares $146,217.00 +21.6%N/A2.5 $4.00
10/15/202030,100 shares $121,002.00 +32.6%N/A2.5 $4.02
9/30/202022,700 shares $87,168.00 -22.5%N/A2.2 $3.84
9/15/202029,300 shares $127,455.00 +70.4%N/A2.9 $4.35
8/31/202017,200 shares $106,812.00 -5.5%N/A2.2 $6.21
8/14/202018,200 shares $119,210.00 -40.9%N/A2.3 $6.55
7/31/202030,800 shares $187,205.48 +76.0%N/A3.3 $6.08
7/15/202017,500 shares $105,175.00 +25.9%N/A2.1 $6.01
6/30/202013,900 shares $88,404.00 -0.7%N/A1.7 $6.36
6/15/202014,000 shares $87,780.00 -23.1%N/A1.4 $6.27
5/29/202018,200 shares $121,030.00 -59.4%N/A1.3 $6.65
5/15/202044,800 shares $300,160.00 +44.5%N/A2.7 $6.70
4/30/202031,000 shares $235,600.00 -13.9%N/A1.9 $7.60
4/15/202036,000 shares $251,100.00 -15.3%N/A2.3 $6.98

IPHA Short Interest - Frequently Asked Questions

What is Innate Pharma's current short interest?

Short interest is the volume of Innate Pharma shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 417,100 shares of IPHA short. 0.73% of Innate Pharma's shares are currently sold short. Learn More on Innate Pharma's current short interest.

What is a good short interest ratio for Innate Pharma?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IPHA shares currently have a short interest ratio of 2.0. Learn More on Innate Pharma's short interest ratio.

What is a good short interest percentage for Innate Pharma?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.73% of Innate Pharma's floating shares are currently sold short.

Is Innate Pharma's short interest increasing or decreasing?

Innate Pharma saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 417,100 shares, a decline of 9.6% from the previous total of 461,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Innate Pharma's short interest compare to its competitors?

0.73% of Innate Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Innate Pharma: Bicycle Therapeutics plc (6.96%), Immunome, Inc. (12.59%), Dianthus Therapeutics, Inc. (26.02%), Pharming Group (0.01%), GH Research PLC (7.12%), KalVista Pharmaceuticals, Inc. (13.20%), uniQure (6.57%), AnaptysBio, Inc. (48.58%), Maravai LifeSciences Holdings, Inc. (4.62%), Organogenesis Holdings Inc. (13.39%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks.

What does it mean to sell short Innate Pharma stock?

Short selling IPHA is an investing strategy that aims to generate trading profit from Innate Pharma as its price is falling. IPHA shares are trading up $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Innate Pharma?

A short squeeze for Innate Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IPHA, which in turn drives the price of the stock up even further.

How often is Innate Pharma's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IPHA, twice per month. The most recent reporting period available is March, 15 2025.




This page (NASDAQ:IPHA) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners